RxDoctor Payments Data

Noor Sachdev, MD

Neurology · San Jose, CANPI 1710141072

Payments from drug & device makers

$282,197in general payments, 2019–2025

Across 1,634 payments — averaging $172.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$120K
  • Argenx US, Inc.$31K
  • Amgen$26K
  • Teva Pharmaceuticals USA, Inc.$21K
  • Biohaven Pharmaceuticals, Inc.$17K
  • AstraZeneca$14K
  • plus $53K from 54 others

What the payments were for

  • Consulting fees$27,08310%
  • Speaking & faculty fees$198,30870%
  • Travel & lodging$23,3508%
  • Food & beverage$32,98912%
  • Education$4680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)257$120,500
Argenx US, Inc.57$31,120
Amgen(2 entities)77$25,723
Teva Pharmaceuticals USA, Inc.74$20,859
Biohaven Pharmaceuticals, Inc.29$17,152
AstraZeneca(2 entities)98$13,995
Lundbeck LLC72$12,340
Lilly USA, LLC39$9,532
Sarepta Therapeutics, Inc.5$6,456
Biohaven Pharmaceutical Holding Company Ltd.9$5,665
UCB, Inc.81$2,078
Eisai Inc.98$1,713
Biogen85$1,604
SK Life Science, Inc.108$1,461
Novartis33$1,117
Johnson & Johnson(2 entities)38$1,096
Neurocrine Biosciences, Inc.40$850
Genentech USA, Inc.27$659
Catalyst Pharmaceuticals, Inc.39$588
Neurelis, Inc.20$556
Pfizer26$508
EMD Serono, Inc.23$420
Harmony Biosciences LLC10$399
CSL Behring15$363
Impel Pharmaceuticals Inc.26$324
Sunovion Pharmaceuticals Inc.27$321
Avanir Pharmaceuticals, Inc.16$301
Kyowa Kirin, Inc.16$252
Sumitomo Pharma America, Inc.15$243
Acorda Therapeutics, Inc11$239
Akcea Therapeutics, Inc.5$232
Amneal Pharmaceuticals LLC7$212
Hospira, Inc.13$210
Acadia Pharmaceuticals Inc10$209
Axsome Therapeutics, Inc.2$201
MDD US Operations, LLC9$178
Otsuka America Pharmaceutical, Inc.7$173
Supernus Pharmaceuticals, Inc.9$167
Sanofi8$163
Tanabe Pharma America, Inc.6$156
Alnylam Pharmaceuticals Inc.6$144
Upsher-smith Laboratories LLC7$142
Octapharma USA, Inc.4$130
Takeda Pharmaceuticals U.S.A., Inc.5$127
Bristol Myers Squibb6$120
Bausch Health US, LLC6$100
Banner Life Sciences, LLC5$95
Adamas Pharmaceuticals, Inc.4$90
Jazz Pharmaceuticals Inc.3$84
Merz Pharmaceuticals, LLC3$73
Portola Pharmaceuticals, LLC3$70
Grifols USA, LLC2$65
Chiesi USA, Inc.4$64
Life Molecular Imaging Ltd5$62
Vertical Pharmaceuticals, LLC3$53
Tersera Therapeutics LLC2$47
Merz North America, Inc.2$46
TG Therapeutics, Inc.1$34
Alfasigma USA, Inc.1$34
Mallinckrodt Hospital Products Inc.2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$282,197 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$323,847
Medicare patients
383
Services billed
16,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine18$544,141
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5019$261,489
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$129,015
NuplazidPimavanserin Tartrate11$53,758
Aimovig AutoinjectorErenumab-Aooe64$48,994
Rivastigmine54$13,572
RytaryCarbidopa/Levodopa12$13,242
Lacosamide48$8,893
Emgality SyringeGalcanezumab-Gnlm11$7,558
Memantine Hcl108$5,294
Levetiracetam106$4,925
Gabapentin166$3,825
Pyridostigmine Bromide19$3,324
Donepezil Hcl221$3,100
Sumatriptan Succinate68$1,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga$508$544,14118 claims
CSL BehringPrivigen$363$261,48919 claims
Grifols USA, LLCGamunex-C$65$129,01512 claims
Acadia Pharmaceuticals IncNuplazid$209$53,75811 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$212$16,56631 claims
Upsher-smith Laboratories LLCTopiramate$142$47321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →